ARRY vs ASML

ARRY's deterministic health scores signal significant distress: the Piotroski F-Score of 2/9 indicates poor financial health, with weak profitability, declining revenue, and high leverage. The absence of an Altman Z-Score raises concern, as the Debt/Equity ratio of 2.94 and negative ROE (-19.02%) suggest elevated bankruptcy risk. Despite a modest Price/Sales of 0.82 and a forward P/E of 7.86, the company's -17.9% YoY revenue decline and negative profit margins undermine valuation appeal. Analysts recommend 'buy' with a $10.07 target, but this optimism appears disconnected from deteriorating fundamentals. The 52-week price range ($3.76–$12.23) and recent 1M drop of 37.6% reflect high volatility and weak market confidence.

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.